An Improved Syngeneic Orthotopic Murine Model of Human Breast Cancer Progression

PURPOSE: Breast cancer drug development costs nearly $610 million and 37 months in preclinical mouse model trials with minimal success rates. Despite these inefficiencies, there are still no consensus breast cancer preclinical models. METHODS: Murine mammary adenocarcinoma 4T1-luc2 cells were implan...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Rashid, Omar M., Nagahashi, Masayuki, Ramachandran, Suburamaniam, Dumur, Catherine, Schaum, Julia, Yamada, Akimitsu, Terracina, Krista P., Milstien, Sheldon, Spiegel, Sarah, Takabe, Kazuaki
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176514/
https://ncbi.nlm.nih.gov/pubmed/25200444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3118-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares